{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:55:38Z","timestamp":1773557738979,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM121293"],"award-info":[{"award-number":["P20GM121293"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bone.2021.115876","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T05:39:36Z","timestamp":1612676376000},"page":"115876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Bone remineralization of lytic lesions in multiple myeloma \u2013 The Arkansas experience"],"prefix":"10.1016","volume":"146","author":[{"given":"Meera","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Samant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Rudy","family":"Van Hemert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erming","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivang","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobhit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Milad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.bone.2021.115876_bb0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11914-017-0397-5","article-title":"Myeloma and bone disease","volume":"15","author":"Panaroni","year":"2017","journal-title":"Current osteoporosis reports."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood cancer journal."},{"key":"10.1016\/j.bone.2021.115876_bb0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bone.2021.115876_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","article-title":"The effects of proteasome inhibitors on bone remodeling in multiple myeloma","volume":"86","author":"Zangari","year":"2016","journal-title":"Bone."},{"issue":"10","key":"10.1016\/j.bone.2021.115876_bb0030","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.3324\/haematol.2016.144477","article-title":"Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jbmr.3111","article-title":"Extensive remineralization of large pelvic lytic lesions following Total Therapy treatment in patients with multiple myeloma","volume":"32","author":"Mohan","year":"2017","journal-title":"Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research."},{"issue":"7","key":"10.1016\/j.bone.2021.115876_bb0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of Arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology."},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0045","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.bone.2021.115876_bb0050","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.bone.2021.115876_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.64","article-title":"Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma","volume":"6","author":"Jethava","year":"2016","journal-title":"Blood Cancer Journal."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2012.160","article-title":"Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?","volume":"27","author":"Usmani","year":"2013","journal-title":"Leukemia."},{"issue":"13","key":"10.1016\/j.bone.2021.115876_bb0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2014-02-555813","article-title":"CYR61\/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease","volume":"124","author":"Johnson","year":"2014","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.bone.2021.115876_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bone.2021.115876_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2008.1.313","article-title":"Skeletal imaging and management of bone disease","author":"Roodman","year":"2008","journal-title":"Hematology American Society of Hematology Education Program."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bone.2021.115876_bb0085","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bone.2021.115876_bb0090","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1101\/gad.4.10.1701","article-title":"The Drosophila segmentation gene runt encodes a novel nuclear regulatory protein that is also expressed in the developing nervous system","volume":"4","author":"Kania","year":"1990","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0095","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/jcb.20891","article-title":"Modulation of mouse RANKL gene expression by Runx2 and PKA pathway","volume":"98","author":"Mori","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2021.115876_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev.genom.9.081307.164437","article-title":"Transcriptional control of skeletogenesis","volume":"9","author":"Karsenty","year":"2008","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"2","key":"10.1016\/j.bone.2021.115876_bb0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.abb.2008.02.030","article-title":"Transcription factors controlling osteoblastogenesis","volume":"473","author":"Marie","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"issue":"Pt 16","key":"10.1016\/j.bone.2021.115876_bb0110","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1242\/jcs.003855","article-title":"Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice","volume":"120","author":"Nissen-Meyer","year":"2007","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.bone.2021.115876_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001372","article-title":"Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk","volume":"7","author":"Duncan","year":"2011","journal-title":"PLoS Genet."},{"issue":"23","key":"10.1016\/j.bone.2021.115876_bb0120","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2014-12-613968","article-title":"Myeloma cell-derived Runx2 promotes myeloma progression in bone","volume":"125","author":"Trotter","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.bone.2021.115876_bb0125","article-title":"Classical and paradoxical effects of TNF-\u03b1 on bone homeostasis","volume":"5","author":"Osta","year":"2014","journal-title":"Front Immunol [Internet]"},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41413-019-0059-6","article-title":"The role of GPCRs in bone diseases and dysfunctions","volume":"7","author":"Luo","year":"2019","journal-title":"Bone Research."},{"issue":"7","key":"10.1016\/j.bone.2021.115876_bb0135","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1359\/jbmr.090210","article-title":"Targeted disruption of the CXCL12\/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss","volume":"24","author":"Diamond","year":"2009","journal-title":"Journal of Bone and Mineral Research : the oFficial Journal of the American Society for Bone and Mineral Research."},{"issue":"5","key":"10.1016\/j.bone.2021.115876_bb0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3111\/13696998.2015.1132225","article-title":"Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma","volume":"19","author":"Nash Smyth","year":"2016","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14815","article-title":"Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival","volume":"179","author":"McIlroy","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2021.115876_bb0150","doi-asserted-by":"crossref","first-page":"115299","DOI":"10.1016\/j.bone.2020.115299","article-title":"No decrease in fracture risk despite 15years of treatment evolution for multiple myeloma patients: a Danish nationwide case-control study","volume":"134","author":"Oortgiesen","year":"2020","journal-title":"Bone."},{"issue":"19","key":"10.1016\/j.bone.2021.115876_bb0155","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1158\/1078-0432.CCR-11-0994","article-title":"A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment","volume":"17","author":"Wu","year":"2011","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research."},{"issue":"2","key":"10.1016\/j.bone.2021.115876_bb0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM200407083510223","article-title":"Bone lesions in molecular subtypes of multiple myeloma","volume":"351","author":"Robbiani","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2021.115876_bb0165","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia."},{"issue":"13","key":"10.1016\/j.bone.2021.115876_bb0170","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.bone.2021.115876_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-142622","article-title":"Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma","volume":"136","author":"Merz","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bone.2021.115876_bb0180","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/0008-5472.CAN-19-0284","article-title":"Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bone.2021.115876_bb0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3324\/haematol.2010.031302","article-title":"A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients","volume":"96","author":"Zangari","year":"2011","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.bone.2021.115876_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074191","article-title":"Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma","volume":"8","author":"Hu","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.bone.2021.115876_bb0205","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1091\/mbc.e17-02-0096","article-title":"Ixazomib enhances parathyroid hormone-induced beta-catenin\/T-cell factor signaling by dissociating beta-catenin from the parathyroid hormone receptor","volume":"28","author":"Yang","year":"2017","journal-title":"Mol. Biol. Cell"},{"issue":"21","key":"10.1016\/j.bone.2021.115876_bb0210","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research."},{"key":"10.1016\/j.bone.2021.115876_bb0215","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis. The cochrane database of systematic reviews","volume":"12","author":"Mhaskar","year":"2017"},{"issue":"2","key":"10.1016\/j.bone.2021.115876_bb0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0225","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bone.2021.115876_bb0230","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0235","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.115876_bb0240","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.bone.2021.115876_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2021.115876_bb0250","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.bone.2021.115876_bb0255","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:39Z","timestamp":1757613279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":51,"alternative-id":["S8756328221000387"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.115876","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone remineralization of lytic lesions in multiple myeloma \u2013 The Arkansas experience","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.115876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115876"}}